Yunlong Richard Cao on X: It's critical to test how these RBD hotspots could combine to achieve max immune evasion without losing affinity to ACE2. After careful consideration, besides the emerging K478R/F456L
The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced Immunity
The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced Immunity
Frontiers Nanobodies: COVID-19 and Future Perspectives
The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced Immunity
Yunlong Richard Cao on X: Our paper on JN.1 is now online @TheLancetInfDis! The manuscript explains how a single RBD mutation L455S could turn BA.2.86 into a heavy immune evasive variant JN.1. Notably, JN.1 is now approaching worldwide
The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced Immunity
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
Yunlong Richard Cao (@yunlong_cao) / X
A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution
